MedTrace Logo

Plasma Dilution and Infusion to Improve Cognition in Mild Cognitive Impairment (MCI)

NCT06234436 · Status: ENROLLING_BY_INVITATION · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-01-31

No results posted yet for this study

Summary

In the ADDITION-MCI project, patients with a diagnosis of mild cognitive impairment probably caused by Alzheimer's disease will receive plasma exchange.

Conditions

  • Alzheimer Disease

Interventions

BIOLOGICAL

Plasma exchenge

Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.

Sponsors & Collaborators

  • Impetus Grants (EIN: 87-1540960)

    collaborator UNKNOWN

  • The National Association for Public Health, Norway

    collaborator OTHER_GOV

  • Vestre Viken Hospital Trust

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-07
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06234436 on ClinicalTrials.gov